
SIGHT
FOR
LIFE
Transforming lives by developing innovative treatments for ocular diseases that helps restore sight for life
2.2 B
people with vision impairement
2.64 B
people who have myopia
460 M
people with high myopia
IMPACT WITH NUMBERS
Theialife's commitment to innovation is reflected in our impressive metrics, demonstrating our impact in ophthalmology
Our lead asset, 7MX is poised to become the first oral therapy for early-onset-pediatric-myopia and is set to enter global Phase III clinical trials in 2025.
This molecular platform has a innovative approach to potentially address neovascular age related macular degeneration & Pterygium.
XP

Our lead molecular platform that has the capability to address various indications including Pediatric Myopia, Dry-Eye Disease & UV-B Cataract.
ND10

Using an innovative approach to drug discovery, this molecular platform is uniquely positioned to address Keratoconus & Corneal blindness.
rHCT3

2o years of real-world clinical usage in Denmark, with nil reported adverse effects.
PROPRIETARY OPTHAMOLOGY PLATFORM
An innovative platform that addresses various ophthalmology unmet needs using novel molecules.
World's First Clinical Phase-3 Ready Oral Therapeutic For Paediatric Myopia
ESG



Daily disposable contact lenses generate approx. 1 KG of plastic waste per year per user


150 Billion contact lenses produced annually


4 Million (approx.) children using contact lenses to treat myopia
VS.
SUSTAINABLE VISIONARY SCIENCE
1 oral tablet of Theialife's drug produced through fermentation using renewable water sources.
0.1 kg CO2 per tablet.
ABOUT
Theialife is a virtual late-clinical stage novel ophthalmology drug company founded on an unyielding commitment to develop innovative breakthrough drug therapies for ophthalmological applications that have unmatched potential to advance the existing standard of care to prevent sight deterioration, restore patient vision and enrich lives.
NOVEL PIPELINE
We have a portfolio of first-in-class molecules that address large-unmet vision-threatening retinal diseases that can lead to further complications, like retinal detachment or blindness.
MYOPIA, THE SILENT EPIDEMIC
Our lead asset, ND10 is poised to become the first oral therapy for early-onset-pedriatric myopia and is set to enter global Phase III clinical trials in 2025.20 Years of real-world clinical usage in Denmark, with nil reported adverse effects.










